Antibody/ADC/AOC Purifications
Monoclonal Antibodies (mAb)
Monoclonal antibody purification begins with harvesting the cell culture supernatant, which contains secreted antibodies produced by the cells. The first step in purification typically involves Protein A affinity chromatography. Protein A, a protein that binds specifically to the Fc region of antibodies, is immobilized on a column and the antibody solution is passed through the column where the antibodies bind while other proteins and impurities are washed away. The bound antibodies are then eluted by altering the pH or using a competitive ligand, ensuring a highly pure antibody fraction. This method is highly selective and widely used due to its efficiency in isolating antibodies from complex mixtures. In addition to Protein A chromatography,other methods such as ion exchange chromatography, size exclusion chromatography, and hydrophobic interaction chromatography can be employed to further purify the antibodies. Ion exchange chromatography separates antibodies based on their charge, while size exclusion can separate them by molecular size. These methods are often used in tandem to refine the purity and remove any remaining impurities or host cell proteins. Antibody purification differs from general protein separations in that antibodies are highly specific, and the purification process must carefully preserve their structural integrity and functionality. Special consideration is also given to the scale of the process, which typically involveslarger volumes and more stringent quality control to meet the demands for therapeutic use.
Antibody-Drug Conjugates and Antibody Peptide Conjugates (ADCs)
ADCs have been proven as an effective drug class for treatment of a number of diseases. Seeing great success in the oncology space, ADCs have begun breaking into other realms through novel drug conjugations. Peptides have also expanded as a therapeutic space, with novel drugs payloads being loaded onto more antibodies than ever before! At Rilas, we leverage our skills in peptide and protein purification to generate highly pure compounds for conjugation, and purifying the conjugates with bespoke methods tailored to your scientific needs.
Antibody-Oligonucleotide Conjugates (AOCs)
Emerging as a new class of therapeutics, antibody-oligonucleotide conjugates look to leverage the tissue targeting and binding specificity of antibodies with the efficacy and potency of oligonucleotide therapeutics. These compounds present their own unique challenges during separation, as the classical methods used for ADCs often break down with these large, highly hydrophilic and negatively charged species. At Rilas, we specialize in leveraging our suite of stationary and mobile phases to find the right conditions for your compound(s) and work with scientist to generate the best samples possible for downstream testing.
Instrumentation:
Agilent 6545XT AdvanceBio LC/Q-TOF
Agilent 1290 Infinity II HPLC/MS
Agilent 1260 HPLC/UV/ELSD